AI-Driven Assessment of Fibrotic and Vascular Changes Correlates with Patient Outcomes in Idiopathic Pulmonary Fibrosis

• by Julien Guiot, Jonne Engelberts, Monique Henket, Benoit Ernst, Quentin Maloir, Renaud Louis, David A. Lynch, Stephen M. Humphries, Jean-Paul Charbonnier

• October 24, 2025

Temple Lung Center: Advancing Research in ILD

Interstitial lung diseases (ILD) significantly impact patient morbidity and mortality. As an ILD Center of Excellence, the Temple Lung Center has established comprehensive programs for the evaluation and management of patients with a wide range of ILDs. This includes extensive clinical research and lung transplantation expertise.

• by

• April 28, 2025

• 2 min

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

• by Kerri Miller

• April 16, 2026

• 3 min

The Role of CONUT Score as a Prognostic Indicator in Progressive Pulmonary Fibrosis: An Accessible Tool for Clinical Risk Assessment

• by Esma Sevil Akkurt, Tugce Sahin Ozdemirel, Berna Akıncı Ozyurek, Kerem Ensarioglu, Ozlem Duvenci Birben, Esma Zenbilli

• November 18, 2025